| Product NDC: | 0007-3373 |
| Proprietary Name: | COREG |
| Non Proprietary Name: | carvedilol phosphate |
| Active Ingredient(s): | 80 mg/1 & nbsp; carvedilol phosphate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0007-3373 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022012 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20070220 |
| Package NDC: | 0007-3373-13 |
| Package Description: | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0007-3373-13) |
| NDC Code | 0007-3373-13 |
| Proprietary Name | COREG |
| Package Description | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0007-3373-13) |
| Product NDC | 0007-3373 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | carvedilol phosphate |
| Dosage Form Name | CAPSULE, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20070220 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | CARVEDILOL PHOSPHATE |
| Strength Number | 80 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],Adrenergic beta1-Antagonists [MoA],Adrenergic beta2-Antagonists [MoA],alpha-Adrenergic Blocker [EPC],beta-Adrenergic Blocker [EPC] |